Corindus
Vascular Robotics

What they're saying about the Company and its opportunity...

"With increasing demand for PCI, physicians are placed not only at higher risk of exposure to x-ray radiation but also to orthopedic related issues over time."

Tal B. Wenderow
Co-Founder of Corindus; Executive Vice President, Marketing & Business Development.



"The CorPath® 200 platform is the first to allow physicians to remotely control the movement of catheters through arteries with a joystick during angioplasties."

Michail M. Pankratov, MD, PhD
Vice President, Clinical and Regulatory Affairs, Corindus Vascular Robotics

"Robotics will aid in the teaching, standardization, and implementation of how catheter-based therapies are delivered to patients—for treatment of vascular disease from the head to the feet."

Peter J. Fitzgerald, MD, PhD
Dir. Ctr. for Cardiovascular Technology, Stanford U. Medical Center; Medical Director and Director, Corindus Vascular Robotics

Precision, Safety, and Standardized Outcomes in the Cath Lab

by Ronald C. Trahan

Percutaneous coronary intervention (PCI) is a procedure used to treat the stenotic (narrowed) coronary arteries of the heart that are found in coronary heart disease. These stenotic segments are the result of a build-up of cholesterol-laden plaques that form due to atherosclerosis.

PCI is performed by an interventional cardiologist in a cath lab utilizing x-ray angiography imaging—which exposes physicians to significant occupational hazards, including radiation exposure as well as chronic orthopedic ailments and fatigue due to the required use of heavy lead-protection garments.

"There are *many* published studies which show that the cath lab is a hazardous work environment, where cardiologist-operators are continually being exposed to increased risk of not only cancer but also spinal problems and cataracts," says **David Handler, President and CEO of Corindus**. "Our CorPath® 200 system is designed to significantly reduce radiation exposure, physician fatigue and other occupational hazards to physicians by allowing him or her to operate in an ergonomically correct position while shielded from harmful radiation exposure," adds Handler, who was previously a senior executive for GE Healthcare's interventional cardiology business.

In addition to physician comfort and safety, CorPath® 200 is designed to elevate cardiologists' precision. Indeed, exact device manipulation is critical in PCI procedures. Currently, these procedures are performed *manually* by physicians while they *stand*, bedside, in a hazardous and stressful environment.

Not surprisingly, in a recent study cardiologists *self*-reported that up to **20% of PCI procedures require placement of a *second* stent due to inexact placement of the first**.

"The CorPath® 200 system is a platform. We expect to commercialize its first clinical application, for PCI, in the next 12 months. Future applications may include peripheral vessel stenting and other complex cases."
David M. Handler
President and CEO

Another published clinical study of 1,557 patients at 42 centers (the 'STLLR' trial) reported that a longitudinal geographic miss (i.e., not accurately treating the lesion's length) occurred in **47.6%** of cases.

"The CorPath® 200 system provides an ergonomic environment, combined with the accuracy and precision that robotics is known for, to potentially benefit both physicians and patients," adds Handler.